Top

Published in:

Open Access 01-12-2018 | Research

Clinical outcome after particle therapy for meningiomas of the skull base: toxicity and local control in patients treated with active rasterscanning

Authors: Rami A. El Shafie, Maja Czech, Kerstin A. Kessel, Daniel Habermehl, Dorothea Weber, Stefan Rieken, Nina Bougatf, Oliver Jäkel, Jürgen Debus, Stephanie E. Combs

Published in: Radiation Oncology | Issue 1/2018

Abstract

Background

Meningiomas of the skull base account for 25–30% of all meningiomas. Due to the complex structure of the cranial base and its close proximity to critical structures, surgery is often associated with substantial morbidity. Treatment options include observation, aggressive surgical intervention, stereotactic or conventional radiotherapy.

In this analysis we evaluate the outcome of 110 patients with meningiomas of the skull base treated with particle therapy. It was performed within the framework of the “clinical research group heavy ion therapy” and supported by the German Research Council (DFG, KFO 214).

Methods

Between May 2010 and November 2014, 110 Patients with skull base meningioma were treated with particle radiotherapy at the Heidelberg Ion Therapy Center (HIT). Primary localizations included the sphenoid wing (n = 42), petroclival region (n = 23), cavernous sinus (n = 4), sella (n = 10) and olfactory nerve (n = 4). Sixty meningiomas were benign (WHO °I); whereas 8 were high-risk (WHO °II (n = 7) and °III (n = 1)). In 42 cases histology was not examined, since no surgery was performed.

Proton (n = 104) or carbon ion (n = 6) radiotherapy was applied at Heidelberg Ion Therapy Center (HIT) using raster-scanning technique for active beam delivery. Fifty one patients (46.4%) received radiotherapy due to tumor progression, 17 (15.5%) after surgical resection and 42 (38.2%) as primary treatment.

Results

Median follow-up in this analysis was 46,8 months (95% CI 39,9–53,7; Q1-Q3 34,3–61,7). Particle radiotherapy could be performed safely without toxicity-related interruptions. No grade IV or V toxicities according to CTCAE v4.0 were observed. Particle RT offered excellent overall local control rates with 100% progression-free survival (PFS) after 36 months and 96.6% after 60 months. Median PFS was not reached due to the small number of events. Histology significantly impacted PFS with superior PFS after 5 years for low-risk tumors (96.6% vs. 75.0%, p = 0,02). Overall survival was 96.2% after 60 months and 92.0% after 72 months from therapy. Of six documented deaths, five were definitely not and the sixth probably not meningioma-related.

Conclusion

Particle radiotherapy is an excellent treatment option for patients with meningiomas of the skull base and can lead to long-term tumor control with minimal side effects. Other prospective studies with longer follow-up will be necessary to further confirm the role of particle radiotherapy in skull base meningioma.

Arvold ND, Niemierko A, Broussard GP, Adams J, Fullerton B, Loeffler JS, et al. Projected second tumor risk and dose to Neurocognitive structures after proton versus photon radiotherapy for benign Meningioma. Int J Radiat Oncol. 2012;83:e495–500. https://doi.org/10.1016/j.ijrobp.2011.10.056.CrossRef

Boskos C, Feuvret L, Noel G, Habrand J-L, Pommier P, Alapetite C, et al. Combined proton and photon conformal radiotherapy for intracranial atypical and malignant Meningioma. Int J Radiat Oncol. 2009;75:399–406. https://doi.org/10.1016/j.ijrobp.2008.10.053.CrossRef

Combs SE, Edler L, Burkholder I, Rieken S, Habermehl D, Jäkel O, et al. Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: the MARCIE trial. BMC Cancer. 2010;10:615. http://www.biomedcentral.com/1471-2407/10/615.CrossRefPubMedPubMedCentral

Combs SE, Adeberg S, Dittmar J-O, Welzel T, Rieken S, Habermehl D, et al. Skull base meningiomas: long-term results and patient self-reported outcome in 507 patients treated with fractionated stereotactic radiotherapy (FSRT) or intensity modulated radiotherapy (IMRT). Radiother Oncol. 2013;106:186–91. https://doi.org/10.1016/j.radonc.2012.07.008.CrossRefPubMed

Vernimmen FJ, Harris JK, Wilson JA, Melvill R, Smit BJ, Slabbert JP. Stereotactic proton beam therapy of skull base meningiomas. Int J Radiat Oncol. 2001;49:99–105. https://doi.org/10.1016/s0360-3016(00)01457-7.CrossRef

Combs SE, Ganswindt U, Foote RL, Kondziolka D, Tonn J-C. State-of-the-art treatment alternatives for base of skull meningiomas: complementing and controversial indications for neurosurgery, stereotactic and robotic based radiosurgery or modern fractionated radiation techniques. Radiat Oncol. 2012;7:226. https://doi.org/10.1186/1748-717x-7-226.CrossRefPubMedPubMedCentral

Condra KS, Buatti JM, Mendenhall WM, Friedman WA, Marcus RB, Rhoton AL. Benign meningiomas: primary treatment selection affects survival. Int J Radiat Oncol. 1997;39:427–36. https://doi.org/10.1016/s0360-3016(97)00317-9.CrossRef

Weber DC, Lomax AJ, Peter Rutz H, Stadelmann O, Egger E, Timmermann B, et al. Spot-scanning proton radiation therapy for recurrent, residual or untreated intracranial meningiomas. Radiother Oncol. 2004;71:251–8. https://doi.org/10.1016/j.radonc.2004.02.011.CrossRefPubMed

Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007;25:953–64. https://doi.org/10.1200/jco.2006.09.7816.CrossRefPubMed

10.

Halasz LM, Bussière MR, Dennis ER, Niemierko A, Chapman PH, Loeffler JS, et al. Proton stereotactic Radiosurgery for the treatment of benign Meningiomas. Int J Radiat Oncol. 2011;81:1428–35. https://doi.org/10.1016/j.ijrobp.2010.07.1991.CrossRef

11.

El Shafie RA, Habermehl D, Rieken S, Mairani A, Orschiedt L, Brons S, et al. In vitro evaluation of photon and raster-scanned carbon ion radiotherapy in combination with gemcitabine in pancreatic cancer cell lines. J Radiat Res. 2013;54(suppl 1):i113–9. http://jrr.oxfordjournals.org/cgi/doi/10.1093/jrr/rrt052.CrossRefPubMedPubMedCentral

12.

Kessel KA, Bohn C, Engelmann U, Oetzel D, Bougatf N, Bendl R, et al. Five-year experience with setup and implementation of an integrated database system for clinical documentation and research. Comput Methods Prog Biomed. 2014;114:206–17. https://doi.org/10.1016/j.cmpb.2014.02.002.CrossRef

13.

National Institutes of Health NCI. Common Terminology Criteria for Adverse Events v4.0 (CTCAE). 2010. Disponible en: https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 19 Dec 2016.

14.

Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343–6. http://www.ncbi.nlm.nih.gov/pubmed/8889347. Accessed 6 Jan 2018CrossRefPubMed

15.

Kessel KA, Fischer H, Oechnser M, Zimmer C, Meyer B, Combs SE. High-precision radiotherapy for meningiomas. Strahlenther Onkol. 2017;193:921–30. https://doi.org/10.1007/s00066-017-1156-3.CrossRefPubMed

16.

Kaul D, Budach V, Wurm R, Gruen A, Graaf L, Habbel P, et al. Linac-based stereotactic radiotherapy and radiosurgery in patients with meningioma. 2014;9:1–9. doi:https://doi.org/10.1186/1748-717X-9-78.

17.

Kaul D, Budach V, Misch M, Wiener E, Exner S, Badakhshi H. Meningioma of the skull base: Long-term outcome after image-guided stereotactic radiotherapy Méningiomes de la base du crâne : résultats à long terme de la radiothérapie stéréotaxique guidée par l’image. Cancer / Radiother. 2014;18:730–5. https://doi.org/10.1016/j.canrad.2014.07.159.CrossRef

18.

Minniti G, Clarke E, Cavallo L, Osti M, Esposito V, Cantore G, et al. Fractionated stereotactic conformal radiotherapy for large benign skull base meningiomas. Radiat Oncol. 2011;6:36. https://doi.org/10.1186/1748-717X-6-36.CrossRefPubMedPubMedCentral

19.

Miralbell R, Cella L, Weber D, Lomax A. Optimizing radiotherapy of orbital and paraorbital tumors: intensity-modulated X-ray beams vs. intensity-modulated proton beams. Int J Radiat Oncol. 2000;47:1111–9. https://doi.org/10.1016/s0360-3016(00)00494-6.CrossRef

20.

Cozzi L, Fogliata A, Lomax A, Bolsi A. A treatment planning comparison of 3D conformal therapy, intensity modulated photon therapy and proton therapy for treatment of advanced head and neck tumours. Radiother Oncol. 2001;61:287–97. https://doi.org/10.1016/s0167-8140(01)00403-0.CrossRefPubMed

21.

Lomax AJ, Cella L, Weber D, Kurtz JM, Miralbell R. Potential role of intensity-modulated photons and protons in the treatment of the breast and regional nodes. Int J Radiat Oncol. 2003;55:785–92. https://doi.org/10.1016/s0360-3016(02)04210-4.CrossRef

22.

Hoskin PJ, Bhattacharya IS. Protons and more: state of the art in radiotherapy. Clin Med. 2014;14(Suppl 6):s61–5. http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25468922&retmode=ref&cmd=prlinks.CrossRef

23.

Bolsi A, Fogliata A, Cozzi L. Radiotherapy of small intracranial tumours with different advanced techniques using photon and proton beams: a treatment planning study. Radiother Oncol. 2003;68:1–14. https://doi.org/10.1016/s0167-8140(03)00117-8. CrossRefPubMed

24.

Kosaki K, Ecker S, Habermehl D, Rieken S, Jäkel O, Herfarth K, et al. Comparison of intensity modulated radiotherapy (IMRT) with intensity modulated particle therapy (IMPT) using fixed beams or an ion gantry for the treatment of patients with skull base meningiomas. Radiat Oncol. 2012;7:44. http://www.ro-journal.com/content/7/1/44.CrossRefPubMedPubMedCentral

25.

Noël G, Bollet MA, Calugaru V, Feuvret L, Haie-Meder C, Dhermain F, et al. Functional outcome of patients with benign meningioma treated by 3D conformal irradiation with a combination of photons and protons. Int J Radiat Oncol. 2005;62:1412–22. https://doi.org/10.1016/j.ijrobp.2004.12.048.CrossRef

26.

Santacroce A, Walier M, Régis J, Liščák R, Motti E, Lindquist C, et al. Long-term tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patients. Neurosurgery. 2012;70:32–9; discussion 39. https://doi.org/10.1227/NEU.0b013e31822d408a.CrossRefPubMed

27.

Murray FR, Snider JW, Bolsi A, Lomax AJ, Walser M, Kliebsch U, et al. Long-term clinical outcomes of pencil beam scanning proton therapy for benign and non-benign intracranial Meningiomas. Int J Radiat Oncol Biol Phys. 2017;99:1190–8. https://doi.org/10.1016/j.ijrobp.2017.08.005.CrossRefPubMed

28.

DiBiase SJ, Kwok Y, Yovino S, Arena C, Naqvi S, Temple R, et al. Factors predicting local tumor control after gamma knife stereotactic radiosurgery for benign intracranial meningiomas. Int J Radiat Oncol. 2004;60:1515–9. https://doi.org/10.1016/j.ijrobp.2004.05.073.CrossRef

29.

Sanford NN, Yeap BY, Larvie M, Daartz J, Munzenrider JE, Liebsch NJ, et al. Prospective, randomized study of radiation dose escalation with combined proton-photon therapy for benign Meningiomas. Int J Radiat Oncol Biol Phys. 2017;99:787–96. https://doi.org/10.1016/j.ijrobp.2017.07.008.CrossRefPubMed

30.

Adeberg S, Hartmann C, Welzel T, Rieken S, Habermehl D, von Deimling A, et al. Long-term outcome after radiotherapy in patients with atypical and malignant Meningiomas—clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. Int J Radiat Oncol. 2012;83:859–64. https://doi.org/10.1016/j.ijrobp.2011.08.010.CrossRef

31.

McDonald MW, Plankenhorn DA, McMullen KP, Henderson MA, Dropcho EJ, Shah MV, et al. Proton therapy for atypical meningiomas. J Neuro-Oncol. 2015;123:123–8. https://doi.org/10.1007/s11060-015-1770-9.CrossRef

32.

Krämer M, Weyrather WK, Scholz M. The increased biological effectiveness of heavy charged particles: from radiobiology to treatment planning. Technol Cancer Res Treat. 2003;2:427–36. http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=14529307&retmode=ref&cmd=prlinks.CrossRefPubMed

33.

Combs SE, Hartmann C, Nikoghosyan A, Jäkel O, Karger CP, Haberer T, et al. Carbon ion radiation therapy for high-risk meningiomas. Radiother Oncol. 2010;95:54–9. https://doi.org/10.1016/j.radonc.2009.12.029.CrossRefPubMed

34.

Phillips MH, Stelzer KJ, Griffin TW, Mayberg MR, Winn HR. Stereotactic radiosurgery: a review and comparison of methods. J Clin Oncol. 1994;12:1085–99. https://doi.org/10.1200/JCO.1994.12.5.1085.CrossRefPubMed

35.

Phillips MH, Frankel KA, Lyman JT, Fabrikant JI, Levy RP. Comparison of different radiation types and irradiation geometries in stereotactic radiosurgery. Int J Radiat Oncol. 1990;18:211–20. https://doi.org/10.1016/0360-3016(90)90286-s.CrossRef

36.

Emami B, Lyman J, Brown A, Cola L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–22.CrossRefPubMed

37.

Smith V, Verhey L, Serago CF. Comparison of radiosurgery treatment modalities based on complication and control probabilities. Int J Radiat Oncol. 1998;40:507–13. https://doi.org/10.1016/s0360-3016(97)00721-9.CrossRef

Title: Clinical outcome after particle therapy for meningiomas of the skull base: toxicity and local control in patients treated with active rasterscanning
Authors: Rami A. El Shafie
Maja Czech
Kerstin A. Kessel
Daniel Habermehl
Dorothea Weber
Stefan Rieken
Nina Bougatf
Oliver Jäkel
Jürgen Debus
Stephanie E. Combs
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2018
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/s13014-018-1002-5

At a glance: The STEP trials

Springer Medicine

Clinical outcome after particle therapy for meningiomas of the skull base: toxicity and local control in patients treated with active rasterscanning

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Evaluation of particle radiotherapy for the re-irradiation of recurrent intracranial meningioma

Analysis of definitive chemo-radiotherapy for esophageal cancer with supra-clavicular node metastasis based on CT in a single institutional retrospective study: a propensity score matching analysis

Fitting NTCP models to bladder doses and acute urinary symptoms during post-prostatectomy radiotherapy

Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis

Delineation of lung cancer with FDG PET/CT during radiation therapy

Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation